Litcius/Paper detail

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Yang Cao, Jia Wei, Liang Zou, Tiebin Jiang, Gaoxiang Wang, Liting Chen, Liang Huang, Fankai Meng, Lifang Huang, Na Wang, Xiaoxi Zhou, Hui Luo, Zekai Mao, Xing Chen, Jungang Xie, Jing Liu, Hui Cheng, Jianping Zhao, Gang Huang, Wei Wang, Jianfeng Zhou

2020Journal of Allergy and Clinical Immunology475 citationsDOIOpen Access PDF

Topics & Concepts

RuxolitinibMedicineInternal medicineClinical trialRandomized controlled trialPlaceboSurgeryPathologyMyelofibrosisBone marrowAlternative medicineCOVID-19 Clinical Research StudiesCytokine Signaling Pathways and InteractionsLong-Term Effects of COVID-19
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial | Litcius